LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Strona główna・Stock List・CytoSorbents Corp

CytoSorbents Corp

Closed

SectorHealthcare

0.56 -8.2

Buy Sell

Overview

Share price change

24h

Current

Min

0.56

Max

0.61

Key metrics
By Trading Economics
Income	-2.3M -5.5M
Sales	-251K 9.2M
Profit margin	-59.526
Employees	129
EBITDA	-766K -3.7M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+22.95% upside

Dividends
By Dow Jones
Next Earnings	13 maj 2026

Market Stats
By TradingEconomics
Market Cap	-3.4M 39M
Previous open	8.76
Previous close	0.56

News Sentiment

By Acuity

93%

337 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.705 / 0.771 Support & Resistance

CytoSorbents Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 maj 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 maj 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 maj 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 maj 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 maj 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 maj 2026, 22:32 UTC

Earnings

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 maj 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 maj 2026, 21:49 UTC

Earnings

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 maj 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 maj 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 maj 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 maj 2026, 21:23 UTC

Acquisitions, Mergers, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 maj 2026, 21:12 UTC

Earnings

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 maj 2026, 21:12 UTC

Earnings

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 maj 2026, 20:44 UTC

Earnings

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 maj 2026, 20:43 UTC

Earnings

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 maj 2026, 20:32 UTC

Earnings

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 maj 2026, 20:32 UTC

Earnings

CleanSpark 2Q Rev $136.4M >CLSK

11 maj 2026, 20:30 UTC

Earnings

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Cont Ops EPS $2.24 >STE

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Rev $1.6B >STE

11 maj 2026, 20:30 UTC

Earnings

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 maj 2026, 20:30 UTC

Earnings

Steris 4Q Adj EPS $2.83 >STE

11 maj 2026, 20:22 UTC

Hot Stocks

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 maj 2026, 19:37 UTC

Earnings

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 maj 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Comparison

Price change

CytoSorbents Corp Forecast

Price Target

By TipRanks

22.95% upside

12 Months Forecast

Average 0.75 USD 22.95%

High 0.75 USD

Low 0.75 USD

Based on 1 Wall Street analysts offering 12 month price targets forCytoSorbents Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to CytoSorbents Corp - Dist in the past 3 months.

Technical Score

By Trading Central

0.705 / 0.771Support & Resistance

All events are bearish.

Sentiment

By Acuity

337 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.